Advertisement

Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series

  • Jacqueline N. Poston
  • Terry B. GernsheimerEmail author
Case Report
  • 64 Downloads

Abstract

A proportion of patients with immune thrombocytopenic purpura are refractory to multiple therapies including thrombopoietin-receptor agonists (TPO-RA). We report 10 patients who did not respond to a TPO-RA until the addition of a glucocorticoid. These patients were previously treated with a median of 6 therapies. One patient elected to discontinue both medications despite persistent thrombocytopenia. The remaining 9 patients continued on the combination of prednisone (doses 5 mg every other day to 10 mg daily) and a TPO-RA. Combination therapy with low dose glucocorticoid and a TPO-RA may be an option for patients unresponsive to a TPO-RA alone.

Keywords

Autoimmune thrombocytopenia Immune thrombocytopenic purpura Refractory Thrombopoietin-receptor agonists Glucocorticoids 

Notes

Acknowledgements

Jacqueline N. Poston receives support from an Institutional Training Grant from the National Heart, Lung, and Blood Institute (T32 HL007093).

Author contributions

JNP and TBG co-wrote the manuscript. JNP analyzed the data.

Compliance with ethical standards

Conflict of interest

Jacqueline N. Poston has no conflicts of interest to disclose. Terry B. Gernsheimer has been a consultant for Amgen and Novartis.

References

  1. 1.
    Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23.  https://doi.org/10.1111/bjh.12260.CrossRefGoogle Scholar
  2. 2.
    Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537–45.  https://doi.org/10.1182/blood-2012-04-425512.CrossRefGoogle Scholar
  3. 3.
    Rashidi A, Blinder MA. Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review. J Clin Pharm Ther. 2016;41(5):453–8.  https://doi.org/10.1111/jcpt.12421.CrossRefGoogle Scholar
  4. 4.
    Arnold DM, Nazi I, Santos A, Chan H, Heddel NM, Warkentin TE, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29–31.  https://doi.org/10.1182/blood-2009-06-222448.CrossRefGoogle Scholar
  5. 5.
    Sivera P, Ruella M, Gueli A, Hu H, Wade M, Tarella C. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagul Fibrinolysis. 2012;23(4):331–4.  https://doi.org/10.1097/MBC.0b013e3283513a97.CrossRefGoogle Scholar
  6. 6.
    Yoon JS, Lee YJ, Baek DW, Park HY, Park BE, Moon JH, et al. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients. Korean J Intern Med. 2018;33(2):435–7.  https://doi.org/10.3904/kjim.2015.252.CrossRefGoogle Scholar
  7. 7.
    Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus. 2014;12(Suppl 1):s149–50.  https://doi.org/10.2450/2013.0289-12.Google Scholar
  8. 8.
    Gomez-Almaguer D, Herrera-Rojas MA, Jaime-Perez JC, Gomez-De Leon A, Cantu-Rodriguez OG, Gutierrez-Aguirre CH, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123(25):3906–8.  https://doi.org/10.1182/blood-2014-01-549360.CrossRefGoogle Scholar
  9. 9.
    Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351–8.Google Scholar
  10. 10.
    Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–65.  https://doi.org/10.1517/14740338.2016.1140743.CrossRefGoogle Scholar
  11. 11.
    Carpenedo M, Cantoni S, Coccini V, Pogliani EM, Cairoli R. Response loss and development of neutralizing antibodies during long-term treatment with romiplostim in patients with immune thrombocytopenia: a case series. Eur J Haematol. 2016;97(1):101–3.  https://doi.org/10.1111/ejh.12733.CrossRefGoogle Scholar
  12. 12.
    Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood. 1978;51(5):771 LP–779.Google Scholar
  13. 13.
    Mizutani H, Furubayashi T, Imai Y, Kashiwagi H, Honda S, Take H, et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW × BXSB) F1. Blood. 1992;79(4):942–7.Google Scholar
  14. 14.
    Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med. 1989;320(15):974–80.  https://doi.org/10.1056/NEJM198904133201505.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Division of Hematology, Department of MedicineUniversity of WashingtonSeattleUSA
  2. 2.Seattle Cancer Care AllianceSeattleUSA
  3. 3.Bloodworks NW Research InstituteSeattleUSA
  4. 4.Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations